GlassScriptPhysician profile
Douglas K Anderson
NPI 1790898807
$8,848.47
in general payments reported to CMS, 2019-2025
24 companies · $3,072 in 2025
The $3,072 reported for 2025 was more than what 94% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,112 · 2020: $348 · 2021: $480 · 2022: $755 · 2023: $2,362 · 2024: $719 · 2025: $3,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,363 · Food and Beverage: $2,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,362.55 |
| Food and Beverage | $2,790.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,960.77 | 2022-2025 | Inspire |
| Smith+Nephew, INC. | $1,776.27 | 2022-2024 | Tula, Coblation, Halo |
| Stryker Corporation | $1,620.89 | 2019-2025 | Scopis Ent, Clarifix Cryotherapy Device, Xpress Loprofile |
| Medical Device Business Services, INC. | $750.49 | 2019 | |
| Optinose US, INC. | $406.92 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $401.26 | 2019-2025 | Dupixent |
| Genzyme Corporation | $366.46 | 2021-2025 | |
| Intersect Ent, INC. | $343.39 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $247.39 | 2019-2025 | Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $222.74 | 2022-2025 | Nucala |
| Acclarent, INC | $130.17 | 2019-2023 | Acclarent Aera, Relieva Spinplus |
| Pharming Healthcare, INC. | $117.85 | 2020 | |
| Aerin Medical INC. | $85.51 | 2021-2024 | |
| Medtronic, INC. | $75.92 | 2022-2023 | Nuvent, Sinuva |
| Amgen INC. | $66.63 | 2024-2025 | Tavneos |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $48.60 | 2025 | Perclot |
| Kowa Pharmaceuticals America, INC. | $46.05 | 2023 | Seglentis |
| Kaleo, INC. | $46.01 | 2020-2022 | |
| Philips North America LLC | $36.47 | 2020 | |
| Shire North American Group INC | $25.43 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.84 | 2023 | Takhzyro |
| Novartis Pharmaceuticals Corporation | $17.81 | 2019 | |
| Phathom Pharmaceuticals, INC. | $16.68 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $13.92 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.